Resources
6 Results (showing 1 - 6)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Treasury Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 11/25/2020 (updated 4/3/2024)
This Peer Support Toolkit from DBHIDS City of Philadelphia is an interactive PDF that presents key information in brief reads, yet preserves your opportunity to delve deeper into subjects—as your time and interests dictate—with just a click. The toolkit is organized in four modules, each addressing specific implementation issues relevant to agencies in various stages of integrating peer support services: 1. Preparation; 2. Interviewing & Hiring; 3. Service Delivery; 4. Supervision & Retention.
Posted 8/4/2021 (updated 4/2/2024)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 6/18/2023 (updated 3/28/2024)
The North Carolina Emergency Department (ED) Peer Support Program enables participating North Carolina hospitals to embed certified peer support specialists in their emergency departments to connect patients presenting with opioid overdose to treatment, recovery, resources and harm reduction supports. This guide is a tool for introducing an ED peer support program in a hospital setting.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.